What is Next for the Genetics of Multiple Sclerosis? by Ramagopalan, Sreeram V. & Dyment, David A.
SAGE-Hindawi Access to Research
Autoimmune Diseases
Volume 2011, Article ID 519450, 3 pages
doi:10.4061/2011/519450
Research Article
What is Next for the Geneticsof Multiple Sclerosis?
SreeramV. Ramagopalan1,2,3 andDavidA.Dyment4
1Wellcome Trust Centre for Human Genetics, University of Oxford, OX3 7BN Oxford, UK
2Department of Clinical Neurology, University of Oxford, OX3 9DU Oxford, UK
3Blizard Institute of Cell and Molecular Science, Queen Mary University of London,
Barts and The London School of Medicine and Dentistry, E1 2AT London, UK
4The Department of Medical Genetics, University of Calgary, Calgary Alberta, Canada T2N 7A1
Correspondence should be addressed to David A. Dyment, david.dyment@calgaryhealthregion.ca
Received 12 January 2011; Accepted 26 January 2011
Academic Editor: Noriko Isobe
Copyright © 2011 S. V. Ramagopalan and D. A. Dyment. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
We review here our current understanding of the genetic aetiology of the common complex neurological disease multiple sclerosis
(MS). The strongest genetic risk factor for MS is the major histocompatibility complex which was identiﬁed in the 1970s. In 2011,
after a number of genome-wide association studies have been completed and have identiﬁed approximately 20 new genes for MS,
we ask the question—what is next for the genetics of MS?
1.Introduction
Hermann Eichorst ﬁrst recognized the familial clustering
of multiple sclerosis (MS) late in the 19th century [1]b u t
it was not until almost a century had passed that it was
ﬁrmly established by population-based studies that relatives
of MS patients have an increased risk for developing the
disease [2]. In keeping with this observation, Davenport
had already made it clear that northern Europeans had
a higher frequency of MS, whereas the disease was much
less common in Asians and Africans [1]. Twin studies and
later an adoption study showed that the observed familial
aggregation was due to shared genes versus any shared
familial exposures [3].
Progress in identifying the genes responsible has, his-
torically, progressed at a glacial pace, despite the early
success with the major histocompatibility complex (MHC)
association. In 1972, MS was shown to be associated with the
MHC[4],laterpinpointedtoaspeciﬁcallele,HLA-DRB1∗15,
of the class II gene HLA-DRB1 [5]. The success in identifying
this association was primarily due to the large eﬀect size of
this region (odds ratio (OR) >2). The next signiﬁcant step
forward occurred in 2007 when new genes were identiﬁed
for MS by genomewide association studies (GWAS) [6].
Now at the dawn of 2011, we have approximately 20 genes
conferring a mild to modest eﬀect(OR < 1.3) on risk that are
robustly associated to MS [7], as well as the long known HLA
association. The question can therefore be posed, is this “job
done” for MS genetics?
2. Discussion
Unfortunately far from it; the associated variants so far
identiﬁed explain about 50% of the inherited risk of MS.
There are several possible explanations as to the “missing”
genetic basis of MS.
It is possible that the immune-related disease loci identi-
ﬁed to date have more of an overall impact on MS risk than
currently estimated. This can result when the marker SNP is
an imperfect proxy for the actual causal mutation that led
to the association signal. There is some evidence to support
this hypothesis in complex disease. Recent resequencing of
63 GWAS-identiﬁed positional candidate genes in Crohn’s
disease identiﬁed three novel low-frequency coding variants
in the IL23R gene [8]. The odds ratios conferred by these
newly detected low frequency variants was approximately
2.4 on average [8]. Although this odds ratio is a possible2 Autoimmune Diseases
overestimation due to winner’s curse, the value appears
larger than the approximate 20% risk increase conferred by
most common variants detected by GWAS. However, the
fact that only 1 out of 63 genes had robustly associated
rare variants and that these newly detected variants jointly
explained only an extra 0.44% of the variance of Crohn’s
disease suggests that rare variants in GWAS-associated genes
are not likely to make a large contribution to inherited
predisposition to complex disease [8].
Perhaps there are additional disease loci than the roughly
20 or so associated genes? These other susceptibility genes
could be identiﬁed by even larger scale GWAS involving
tens or hundreds of thousands of MS patients and controls.
The GWAS published so far in MS have not exceeded 2000
patients in the initial (screening) phase. Statistical modelling
has suggested that 12,627 SNPs explains approximately
3% of the variance in MS risk [9]. We await the results
of the MS GWAS funded by the Wellcome Trust which
involves tens of thousands of participants to see if the vast
resourcesexpendedinsuchaprojectaretranslatedintonovel
insights into MS aetiology. It should be remembered that
MS is phenotypically a heterogeneous disease [1], and while
current GWAS have used unselected patient populations to
identify disease associations, this may miss variants more
important to certain patient groups.
Another explanation may be that some disease loci may
contain only rare variants. In order to identify these genes a
sequencing-based approach would be required. In the past
this was not possible given the cost and technology available;
however recent advances in next-generation sequencing
technologies (whole exome and whole genome sequencing)
could rapidly facilitate the identiﬁcation of these variants
that would be too rare to be picked up by GWAS. These rare
variants would be expected to be causal and have a relatively
large eﬀect on risk (i.e., OR > 3). The 1000-Genomes project
has highlighted the fact that each of us has 250 to 300 loss-
of-function variants in our genes [10]. However, for complex
diseases, power considerations will be an issue to cope with
the wealth of data generated by whole genome sequenc-
ing. It has been suggested that whole-exome sequencing
will be most fruitful in identifying rare disease causative
variants in families that have multiple aﬀected individuals
[11].
SNPs are only one type of genetic variation. It has
been observed that individual copies of the human genome
contain large regions (tens to hundreds of kilobases in
size) that are deleted, duplicated, or inverted relative to the
reference sequence. These structural variants may contribute
to MS aetiology but have not yet been adequately tested.
H o w e v e r ,as t u d yb yt h eW e l l c o m eT r u s tC a s eC o n t r o lC o n -
sortiumobservedthatmostcommonstructuralvariationare
well tagged by SNPs and so have been indirectly explored
through genomewide SNP studies and therefore concluded
that common structural variants are unlikely to contribute
greatly to the genetic basis of common human diseases [12].
Moving on from single locus associations to consider
biological systems, it may be that gene-gene and gene-
environment interactions may play an important role in
disease. Once patterns of association and interaction are
better understood, the eﬀects of speciﬁc gene and envi-
ronmental exposures on developing MS may be signiﬁcant.
Indeed epistatic interactions exist between MHC haplotypes
[13] and can greatly alter risk. For example, HLA-DRB1∗08,
interacts with HLA-DRB1∗15 to more than double the risk
associated with a single copy of HLA-DRB1∗15 [13]. On
its own, HLA-DRB1∗08 increases the risk of MS modestly,
highlighting that a variant with a small marginal eﬀect is not
necessarily clinically insigniﬁcant; it may turn out to have
as t r o n ge ﬀect in certain genetic backgrounds. As yet, no
functional explanation can be given for these interactions;
understanding the mechanism of these interactions will be
critical to further understanding MS aetiology.
Epigenetic contributions may also play an important role
in MS. Epidemiological data strongly hints at a parent-of-
origin eﬀect in MS [14]. For example, maternal half-siblings
have double the risk for MS as compared to paternal half-
siblings (2.35% versus 1.31%) [14]. Risk for MS in maternal
half-siblings compared to their full siblings does not diﬀer
signiﬁcantly [14] suggesting that this maternal eﬀect is a
major component of familial aggregation of the disease.
The mechanism of the increased risk conferred maternally
remains to be elucidated but epigenetic mechanisms such
as DNA methylation and histone modiﬁcation may regulate
genomic function in such a way to increase MS risk [15].
A recent study investigating these eﬀects utilized next-
generation sequencing in discordant twins. The investigators
could not ﬁnd evidence for any epigenetic diﬀerences
between the twins to explain the MS discordance [16]. How-
ever, there were a number of limitations to the study design
used, and it is of interest that DNA methylation diﬀerences
have been shown to exist between twins discordant for
systemic lupus erythematosus [17]a n df o rp a r e n to fo r i g i n
eﬀects in type 2 diabetes [18].
3. Conclusion
As with all complex diseases, the genetics of MS has not yet
been fullyelucidated. While GWAS have been responsible for
a wealth of new information these association studies have
not provided all the answers for MS risk. We are now in
an era of very exciting potential applications of sequencing
technology. Next-generation sequencing platforms allow us
to survey multiple levels of natural variation at unprece-
dentedresolutionanddepth.Assequencingcostscontinueto
decrease, and both laboratory and computational protocols
improve, we will see ever increasing use of this technology,
hopefully enabling us to completely unlock the complex
genetic basis of MS. There is unlikely to have a single
answer, with interactions, rare variants, epigenetic factors
all likely to be contributing. Ultimately, well-performed
functional studies will be required to understand how all
these risk factors interact to predispose to MS. Against
this it will be debated whether further genetic research
will actually advance our understanding of MS. However,
the motivation for future work is the need to understand
disease mechanisms to derive safe and eﬀective treatments
and ultimately to prevent the disease.Autoimmune Diseases 3
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